Jazz Sues Alvogen Seeking to Block Copy of Defitelio Liver Drug

An Alvogen Group Inc. subsidiary’s proposed copy of Jazz Pharmaceuticals Plc’s Defitelio infringes three patents for the drug, which treats blocked veins in the liver, a federal lawsuit said.

Almaject Inc.'s generic version of the treatment for hepatic veno-occlusive disease infringes US Patent Nos. 11,085,043, 11,236,328, and 11,746,348, according to a complaint filed Wednesday in the US District Court for the District of New Jersey.

• The patents are held by Jazz’s Gentium SRL unit, a co-plaintiff, and cover the specific formulations of Defitelio and methods for using defibrotide, its active ingredient, to treat blocked veins in the ...